ReviewCost effectiveness and resource allocation : C/E2026

A systematic review of the cost-utility of dapagliflozin for managing chronic kidney disease.

Ronald Watema-Lord et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.